Core Viewpoint - The recent antitrust penalties against three pharmaceutical companies in China highlight the exploitation of market concentration to inflate drug prices, particularly during the COVID-19 pandemic, raising concerns about unethical practices in the industry [1][7]. Group 1: Antitrust Case Details - Tianjin Municipal Market Supervision Administration imposed a total fine of 326 million yuan on Tianjin Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, and Xianju Pharmaceutical for colluding to manipulate the price of Dexamethasone Sodium Phosphate [1][7]. - The price of Dexamethasone Sodium Phosphate surged from approximately 7,900 yuan per kilogram in November 2021 to 45,000 yuan per kilogram by November 2023, indicating a significant price manipulation [1][5]. Group 2: Market Dynamics - The concentration of market competition is a key factor enabling these companies to control raw material and formulation prices, with the three companies holding four out of eight approved production licenses for Dexamethasone Sodium Phosphate [3][4]. - The demand for Dexamethasone Sodium Phosphate injections increased significantly during the pandemic, allowing companies to profit even as costs rose, leading to further price hikes [4][5]. Group 3: Regulatory Environment - The Chinese government has adopted a "zero tolerance" approach towards monopolistic behaviors in the pharmaceutical sector, as evidenced by the total fines of 1.772 billion yuan for antitrust cases in 2023 [7]. - The ongoing normalization of national medical insurance procurement and the enhancement of antitrust regulatory frameworks are expected to reduce the gray areas of vertical monopolies in the pharmaceutical industry [7].

Core Viewpoint - The article discusses the significant impact of antitrust penalties on the financial performance of Xianju Pharmaceutical and other companies involved in price-fixing agreements for dexamethasone phosphate raw materials during the COVID-19 pandemic [1][3]. Group 1: Antitrust Penalties - Xianju Pharmaceutical was fined 195 million yuan for monopolistic practices, which accounts for 4.88% of its 2024 revenue and 49.17% of its net profit [1]. - Tianyao Pharmaceutical and Lianhuan Pharmaceutical were also penalized, with fines of 69.19 million yuan and 61.04 million yuan, respectively [1]. - The companies formed a price alliance, raising the price of dexamethasone phosphate from 0.35 yuan to a peak of 98.76 yuan, an increase of nearly 282 times [1]. Group 2: Financial Impact on Companies - In 2024, Xianju Pharmaceutical's net profit fell by 29.46% to 397 million yuan, largely due to the antitrust fine [2][4]. - The cash flow from operating activities for Xianju Pharmaceutical decreased by 33.05%, and cash reserves dropped by 16.76% [4]. - Tianyao Pharmaceutical's revenue in 2024 was 3.215 billion yuan, down 15%, but its net profit increased by 14% due to the fine being accounted for in 2025 [6][7]. Group 3: Market Adjustments and Strategies - Xianju Pharmaceutical is shifting its product structure and expanding into overseas markets to mitigate the impact of declining revenues from dexamethasone products [5]. - The company is focusing on high-margin areas such as respiratory and dermatological products, with sales in respiratory products growing by 31% in 2024 [5]. - Tianyao Pharmaceutical's steroid raw material business also saw a revenue decline of 16.9% in 2024, indicating broader market pressures [7]. Group 4: Ongoing Challenges - Tianyao Pharmaceutical has faced multiple antitrust penalties over the past four years, indicating a pattern of regulatory scrutiny [8]. - Lianhuan Pharmaceutical's future penalties remain uncertain as it plans to appeal the decision, highlighting the ongoing challenges within the industry [8].

在竞争激烈的医药市场中，津药药业积极应对挑战，通过优化公司治理结构、加强信息披露管理等举 措，不断提升企业的综合实力与市场竞争力，为实现可持续发展奠定坚实基础。 优化治理架构，夯实发展基石 2024年，津药药业董事会充分发挥核心领导作用，面对复杂多变的市场环境，秉持公司长远发展愿景， 审慎规划战略布局。这一年，董事会共召开9次会议，董事们积极参与，对公司重大决策进行深入探讨 与审议，确保决策的科学性与有效性；监事会作为公司治理的重要监督力量，在2024年同样发挥了关键 作用。全年共召开6次会议，对公司资本运作、经营管理、财务状况以及高级管理人员履职情况进行全 面监督。 在监督与管理方面，津药药业强化内部管理机制，提升风险防控能力。审计与风险控制委员会严格审查 公司内控及财务报表，独立董事持续监督关联交易，切实维护中小投资者权益。同时，津药药业根据法 律法规及公司实际需求，对专门委员会进行更名并扩充职责，修订多项公司治理制度，包括《公司章 程》《股东大会议事规则》等，为公司规范运作提供了坚实的制度保障。 加强信息披露，搭建沟通桥梁 信息披露是公司与资本市场沟通的重要桥梁，津药药业高度重视此项工作。2024年度， ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600488 证券简称：津药药业 编号：2025-029 津药药业股份有限公司 关于收到行政处罚决定书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 2025年4月30日，津药药业股份有限公司（以下简称"公司"）收到天津市市场监督管理委员会下发的 《行政处罚决定书》（津市监垄处〔2025〕1号），现将相关情况公告如下： 一、决定书主要内容 天津市市场监督管理委员会认为，公司与具有竞争关系的其他经营者，就地塞米松磷酸钠原料药所实施 的一系列行为，违反了《反垄断法》第十七条第（一）项的规定，属于达成并实施"固定或者变更商品 价格"垄断协议的行为，应当依据《反垄断法》第五十六条的规定依法追究法律责任。 根据《反垄断法》第五十六条第一款、第五十九条，综合考虑公司违法行为的性质、程度、持续时间、 消除违法后果的情况、积极进行整改等因素，天津市市场监督管理委员会责令公司停止违法行为，并作 出行政处罚如下：（一）没收违法所得 42,764,400.00元；（二）并处2 ...

【导读】津药药业违反《反垄断法》被罚没6919.24万元 中国基金报记者 江右 因为与其他经营者实施了违反《反垄断法》的行为，津药药业收到行政处罚决定书，被罚没6919.24万元。 实施垄断行为，被罚没6919.24万元 4月30日收盘后，上市公司津药药业披露当天收到天津市市场监督管理委员会下发的《行政处罚决定书》。 津药药业表示，天津市市场监督管理委员会认为，公司与具有竞争关系的其他经营者，就地塞米松磷酸钠原料药所实施的一系列行为，违反了《反垄断 法》第十七条第（一）项的规定，属于达成并实施"固定或者变更商品价格"垄断协议的行为，应当依据《反垄断法》第五十六条的规定依法追究法律责 任。 根据《反垄断法》第五十六条第一款、第五十九条，综合考虑公司违法行为的性质、程度、持续时间、消除违法后果的情况、积极进行整改等因素，天津 市市场监督管理委员会责令公司停止违法行为，并作出行政处罚如下：（一）没收违法所得42,764,400.00元；（二）并处2023年度销售额8%的罚款 132,139,751.80元，结合宽大情形，减免罚款额的80%，减免后实际罚款26,427,950.36元。以上罚没款合计69,192,35 ...

地塞米松磷酸钠具有抗炎、抗过敏、抗风湿、免疫抑制作用，常用于过敏及自身免疫性疾病。贝壳财经 记者在国家药监局官网查询发现，目前，地塞米松磷酸钠原料药有多个批文，生产单位包括津药药业、 上海新华联制药有限公司、仙琚制药、西安国康瑞金制药、江苏联环药业等。 针对行政处罚对公司影响，津药药业在公告中表示，上述罚没款合计金额占公司2024年经审计的营收、 归母净利润的比例分别为2.15%和51.85%。 公司进一步表示，目前地塞米松磷酸钠原料药产品生产和销售情况正常。上述罚没款合计金额将相应减 少公司2025年归母净利润6919.23万元。 津药药业称，已责令相关部门第一时间组织整改，采取四方面整改措施。整改措施提及，已制定可落实 的销售方案，发布了降价通知，主动下调地塞米松磷酸钠原料药价格，确保药品供应。 根据津药药业发布的今年一季度报告，报告期内，公司营业收入约7.86亿元，同比减少9.03%；归母净 利润5805.01万元，同比增长0.07%。 随着多家上市公司披露《行政处罚决定书》，针对地塞米松磷酸钠原料药的垄断行为正在逐步浮出水 面。 4月30日，津药药业发布公告表示，因涉及达成并实施"固定或者变更商品价格 ...

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

Core Viewpoint - Tianjin Pharmaceutical Industry is recognized as a leading domestic manufacturer of steroid hormone drugs and a global leader in amino acid raw materials, showcasing its advanced position and demonstration effect in the industry for the year 2024 [1] Product Matrix - The company has a diverse product matrix with over 70 types of raw materials, including dexamethasone series, prednisone series, methylprednisolone series, betamethasone series, and amino acids, as well as more than 10 dosage forms such as injections, ointments, and tablets, catering to various patient treatment needs [2] R&D Innovation - In recent years, the company has significantly enhanced its product R&D and scientific research system, focusing on steroid hormones and amino acids, and implementing a "raw materials + formulations" full industry chain layout, with R&D investment reaching 248 million yuan in 2024, accounting for 7.7% of revenue, reflecting its strong R&D capabilities [3] Dual-Track Strategy - The company employs a dual-track strategy of "innovation line" and "generic line" to accelerate the new drug approval process, with 11 specifications of 10 products recently receiving approval, including the first domestic approval for a specific injection by its subsidiary [4] Market Performance - Among its products, the injection of isopropyl methochloride has shown strong market performance, with sales increasing from 756 million yuan in 2022 to 821 million yuan in 2023, and is expected to expand further due to its inclusion in the national medical insurance [5] - The inhalation solution of acetylcysteine is also a national medical insurance drug, with significant market potential in treating respiratory diseases, indicating a stable growth outlook as the patient population expands [5] Future Outlook - The company plans to continue its commitment to innovation, increasing investment in technology R&D, and focusing on new product development and consistency evaluation to provide high-quality, efficient drugs for patients and deliver substantial value returns to shareholders [6]

证券代码：600488 证券简称：津药药业 编号：2024-030 津药药业股份有限公司 关于子公司注射用甲泼尼龙琥珀酸钠 近日，津药药业股份有限公司（以下简称"公司"）子公司津药和平（天 津）制药有限公司（以下简称"津药和平"） 注射用甲泼尼龙琥珀酸钠（以 下简称"该药品"）获得多米尼加共和国卫生部注册证书（标志着可以生产 并在多米尼加共和国市场销售该产品），现将相关信息公告如下： 一、药品的基本情况 二、药品的其他相关情况 注射用甲泼尼龙琥珀酸钠是一种糖皮质激素类药物，主要用于抗炎治疗、 免疫抑制治疗、血液疾病和肿瘤的治疗、休克的治疗等。2023 年津药和平向 多米尼加共和国卫生部提出注册申请，2025 年 4 月收到卫生部通知，取得注 册证书。 注 射 用 甲 泼 尼 龙 琥 珀 酸 钠 原 研 厂 家 为 美 国 辉 瑞 ， 商 品 名 为 SOLU-MEDROL，最早于 1959 年在美国上市，随后陆续在欧洲、中国、日本 等主流国家上市并销售。根据 IQVIA 数据库显示，甲泼尼龙类注射剂 2023 年、2024 年全球市场销售额分别为 5.26 亿美元、5.21 亿美元。 三、对上市公司影响及风险 ...

证券代码：600488 证券简称：津药药业 编号：2025-029 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司 2025 年 4 月 30 日，津药药业股份有限公司（以下简称"公司"）收到 天津市市场监督管理委员会下发的《行政处罚决定书》（津市监垄处〔2025〕 1 号），现将相关情况公告如下： 关于收到行政处罚决定书的公告 一、决定书主要内容 天津市市场监督管理委员会认为，公司与具有竞争关系的其他经营者， 就地塞米松磷酸钠原料药所实施的一系列行为，违反了《反垄断法》第十 七条第（一）项的规定，属于达成并实施"固定或者变更商品价格"垄断 协议的行为，应当依据《反垄断法》第五十六条的规定依法追究法律责任。 根据《反垄断法》第五十六条第一款、第五十九条，综合考虑公司违 法行为的性质、程度、持续时间、消除违法后果的情况、积极进行整改等 因素，天津市市场监督管理委员会责令公司停止违法行为，并作出行政处 罚如下：（一）没收违法所得 42,764,400.00 元；（二）并处 2023 年度销售 额 8%的 ...